Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …

Triple negative breast cancer (TNBC) has a negative expression of estrogen receptors (ER),
progesterone receptors (PR), and human epidermal growth factor receptors (HER2). The …

Simple Summary Breast cancer is the most common cancer among women. It is estimated
that 2.3 million new cases of BC are diagnosed globally each year. Based on mRNA gene …

The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and
progression are being increasingly defined. The TRACERx Renal studies and others that …

As the field of translational 'omics has progressed, refined classifiers at both genomic and
proteomic levels have emerged to decipher the heterogeneity of breast cancer in a clinically …

We comprehensively analyzed clinical, genomic, and transcriptomic data of a cohort of 465
primary triple-negative breast cancer (TNBC). PIK3CA mutations and copy-number gains of …

Triple-negative breast cancer (TNBC) cells are deficient in estrogen, progesterone and
ERBB2 receptor expression, presenting a particularly challenging therapeutic target due to …

Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer
strategy. Several lines of evidence support the study of immunotherapy in triple-negative …

Drug sensitivity and resistance are conventionally quantified by IC50 or E max values, but
these metrics are highly sensitive to the number of divisions taking place over the course of …

Estrogen receptor (ER)-positive luminal breast cancer is a subtype with generally lower risk
of metastasis to most distant organs. However, bone recurrence occurs preferentially in …